NDA 216873 · Glaxosmithkline
Ojjaara
Momelotinib Dihydrochloride · Oral
NovelOrphanCDER novel approval, Sep 15, 2023: To treat intermediate or high-risk myelofibrosis in adults with anemia
Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Sep 15, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
1,481
978 serious, 230 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 20, 2026.
OJJAARA is indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. OJJAARA is a kinase inhibitor indicated for the treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF or secondary MF [post‑polycythemia vera (PV) and post‑essential thrombocythemia (ET)], in adults with anemia. ( 1 )
Mechanism: Momelotinib is an inhibitor of wild type Janus Kinase 1 and 2 (JAK1/JAK2) and mutant JAK2 V617F , which contribute to signaling of a number of cytokines and growth factors that are important for hematopoiesis and immune function. Momelotinib and its major human circulating metabolite, M21, have higher inhibitory activity for JAK2 compared to JAK3 and tyrosine kinase 2 (TYK2). Momelotinib and M21 additionally inhibit activin A receptor type 1 (ACVR1), also known as activin receptor like kinase 2 (ALK2), which produces subsequent inhibition of liver hepcidin expression and increased iron...
Therapeutic areas: Hematology and blood cancers
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
3 products under this application
- OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 200MG BASE · TABLET, ORAL · Prescription
- OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 100MG BASE · TABLET, ORAL · Prescription
- OJJAARA · MOMELOTINIB DIHYDROCHLORIDE EQ 150MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Momelotinib Dihydrochloride" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death113
- thrombocytopenia112
- myelofibrosis96
- drug ineffective90
- anaemia86
- diarrhoea78
- pneumonia74
- fatigue72
- haemoglobin decreased66
- dizziness63
- hospitalisation63
- platelet count decreased62
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 3 |
| 2019 | 4 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 67 |
| 2024 | 381 |
| 2025 | 580 |
| 2026 | 430 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Ojjaara (Momelotinib Dihydrochloride)
2024 spending
$342M
Beneficiaries
2,316
12,239 claims
Per beneficiary
$147,536
$912.19 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $27,017,098 |
| 2024 | $341,692,382 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.